论文部分内容阅读
目的分析及探讨慢阻肺合并冠心病的临床诊断及治疗的有效情况。方法收集2014年6月至2016年6月到本医院接受临床诊断及治疗的58例慢阻肺合并冠心病患者的存档病例,按其临床给予的不同药物治疗进行不同小组的归类,分为29例对照组和29例研究组,对照组的慢阻肺合并冠心病患者均进行常规药物治疗,而研究组的患者均在对照组治疗方案的基础上再服用美托洛尔药物治疗,观察及对比两组患者治疗4个月后的病症改善效果。结果治疗前与治疗四个月后,两组慢阻肺合并冠心病患者的治疗有效情况分别为:常规药物治疗的对照组总有效率的统计结果为72.41%(21/29),而应用美托洛尔治疗的研究组总有效率的统计结果为96.55%(28/29)。经统计观察可得,研究组的疗效则明显优异于对照组,统计性差异显著存在(P<0.05)。结论临床对慢阻肺合并冠心病的诊断中很容易出现误诊情况,故而临床医生要十分重视这两种病症的鉴别诊断,并在治疗中不断探求其发病因素,以寻找到最佳的治疗方案。本文中应用了美托洛尔进行慢阻肺合并冠心病的治疗,其应用疗效好、安全性高、药性持久、疗效可靠,能更有效改善临床相应的各种病症,促进心肌功能的快速恢复,值得临床在治疗慢阻肺合并冠心病疾病时推广美托洛尔的应用。
Objective To analyze and discuss the clinical diagnosis and treatment of COPD complicated by coronary heart disease. Methods Fifty-eight patients with chronic obstructive pulmonary disease and coronary heart disease who underwent clinical diagnosis and treatment in our hospital from June 2014 to June 2016 were enrolled in this study. According to the different clinical treatments, different groups were classified into 29 cases of control group and 29 cases of study group, the control group of patients with chronic obstructive pulmonary disease and coronary heart disease were treated with conventional drugs, while the study group patients were treated with metoprolol in the control group on the basis of medication, the observation And compare the two groups of patients after treatment for 4 months to improve the effect of the disease. Results Before treatment and four months after treatment, the curative effect of COPD patients with coronary heart disease were 72.41% (21/29) in the control group of conventional drug treatment, while the application of the United States The total effective rate of the group treated with Tolol was 96.55% (28/29). Statistics show that the efficacy of the study group was significantly better than the control group, statistically significant differences (P <0.05). Conclusion Clinical diagnosis of COPD with coronary heart disease is prone to misdiagnosis, so clinicians should attach great importance to the differential diagnosis of these two diseases, and continue to explore the treatment of its risk factors in order to find the best treatment . In this paper, metoprolol is used for the treatment of COPD with coronary heart disease. Its application has good curative effect, high safety, durable medicine and reliable curative effect, and can effectively improve various clinically relevant diseases and promote rapid recovery of myocardial function , Worth the clinical application of metoprolol in the treatment of COPD with coronary heart disease.